Clinical Lymphoma Myeloma and Leukemia 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Immunoglobulin high throughput sequencing (Ig-HTS) minimal residual disease (MRD) analysis is an effective surveillance tool in patients with mantle cell lymphoma
Mantle cell lymphoma accounts for 4-6% of B-cell non-Hodgkin lymphoma (NHL) with historically poor outcomes. With the advent of intensive first-line, targeted, and cellular therapies, outcomes have improved, and initial remission can be 8-10 years or even longer. As patients experience longer remissions, this raises the question of the optimal surveillance modality. Peripheral blood minimal residual disease (MRD) analysis offers a potential alternative to surveillance imaging that sensitive, less costly, and eliminates the risk of radiation exposure. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 9, 2023 Category: Hematology Authors: Alexandra Rezazadeh, Julie Pruett, Amy Detzner, Natasha Edwin, Mehdi Hamadani, Nirav N. Shah, Timothy S. Fenske Tags: Original Study Source Type: research
Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study
Despite treatment advances that have improved patient survival, including immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies (mAbs), multiple myeloma (MM) remains incurable.1,2 Most patients ultimately relapse or become refractory to standard drug classes.3,4 Triple-class exposed patients with relapsed/refractory MM (RRMM) have particularly aggressive disease and a poor prognosis.5 This may, in part, be due to the increasing genetic complexity and more drug-resistant mutations that occur with each new line of therapy (LOT), particularly for patients with high-risk cytogenetics....
Source: Clinical Lymphoma, Myeloma and Leukemia - December 6, 2023 Category: Hematology Authors: Maria-Victoria Mateos, Katja Weisel, Joris Diels, Alberto Arribas, Maria Tamayo, Jordan M. Schecter, Tito Roccia, Im ène Haddad, Lida Pacaud, Philippe Moreau Tags: Original Study Source Type: research
The prognostic significance of vitamin D deficiency in Korean patients with multiple myeloma
This study aimed to assess the prognostic value of vitamin D levels in this Korean patient population. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 5, 2023 Category: Hematology Authors: Sejin Kim, Hyungwoo Cho, Miyoung Kim, Kyoungmin Lee, Shin Kim, Dok Hyun Yoon Tags: Original Study Source Type: research
Folinic Acid Over: Rescue of Intermediate Dose Methotrexate
The article published by Haran et al.1 is an important addition to the efforts being made to improve the use of methotrexate (MTX) in malignant disorders. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 4, 2023 Category: Hematology Authors: Ian J. Cohen Tags: Letter to the Editor Source Type: research
Folinic acid over - rescue of intermediate dose methotrexate
Dear Sir, (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 4, 2023 Category: Hematology Authors: Ian J Cohen Tags: Letter to the Editor Source Type: research
SOHO State of the Art Updates and Next Questions: Oral Therapy in Acute Myeloid Leukemia
With the recent development of several new effective agents, treatment of patients with acute myeloid leukemia (AML) is evolving. Molecularly targeted agents developed against leukemogenic pathways are demonstrating significant promise both as monotherapy and in combination with standard regimens. Although oral chemotherapeutic agents have long been used in the treatment of various malignancies, their use in patients with AML has been hitherto limited. The availability of most newly approved targeted agents in oral formulation has provided us with the potential for developing all oral regimens in AML. (Source: Clinical Lym...
Source: Clinical Lymphoma, Myeloma and Leukemia - December 1, 2023 Category: Hematology Authors: Patrice Nasnas, Farhad Ravandi Tags: Review Article Source Type: research
SOHO State of the Art Updates and Next Questions | Oral Therapy in Acute Myeloid Leukemia
With the recent development of several new effective agents, treatment of patients with acute myeloid leukemia (AML) is evolving. Molecularly targeted agents developed against leukemogenic pathways are demonstrating significant promise both as monotherapy and in combination with standard regimens. Although oral chemotherapeutic agents have long been used in the treatment of various malignancies, their use in patients with AML has been hitherto limited. The availability of most newly approved targeted agents in oral formulation has provided us with the potential for developing all oral regimens in AML. (Source: Clinical Lym...
Source: Clinical Lymphoma, Myeloma and Leukemia - December 1, 2023 Category: Hematology Authors: Patrice Nasnas, Farhad Ravandi Tags: Review Article Source Type: research
Predictors and impact of timing of disease progression following primary therapy in multiple myeloma
We examined the outcomes of 1557 MM patients stratified into short (5 years) PFS. Short PFS occurred in 758 patients (48.7%), medium in 561 patients (36.2%), and long in 238 patients (15.3%). Median post-progression PFS was 9.2 months (95% CI 8.1-11.0) in the short PFS and 33.1 months (95% CI 29.0-42.1; p (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 27, 2023 Category: Hematology Authors: Sarah Goldman-Mazur, Alissa Visram, S. Vincent Rajkumar, Prashant Kapoor, Angela Dispenzieri, Martha Q. Lacy, Morie A. Gertz, Francis K. Buadi, Suzanne R. Hayman, David Dingli, Taxiarchis Kourelis, Wilson Gonsalves, Rahma Warsame, Eli Muchtar, Nelson Leun Tags: Original Study Source Type: research
Multiparametric Flow Cytometry in the Evaluation of Plasma Cell Proliferative Disorders: Current Paradigms for Clinical Practice
The multi-parametric flow cytometry (MFC) is technically the most valuable tool in characterization and quantification of clonal plasma cells (PCs). The MFC has a well-defined role in monitoring measurable residual disease (MRD) in MM, in estimating risks of progression in MGUS and SMM and predicting treatment outcomes. The ability of MFC to measure low levels of circulating clonal PCs has enabled non-invasive monitoring of treatment responses and risk assessment in PCPDs. The study of changes in the tumor microenvironment makes it an attractive platform to understand impact of newtherapies, especially, the immunotherapy. ...
Source: Clinical Lymphoma, Myeloma and Leukemia - November 26, 2023 Category: Hematology Authors: Ritu Gupta, Dragan Jevremovic, Smith J. Mathew, Shaji Kumar Tags: Review Article Source Type: research
SOHO State of the Art Update and Next Questions: Novel Therapies for Polycythemia Vera
In the recent years, landmark advancements in the treatment of polycythemia vera (PV) have been achieved. We witnessed the regulatory approval of ropeginterferon and the advanced clinical development of other novel agents that may affect the underlying pathophysiological mechanisms of the disease. Agents with the potential of disease modification may soon overtake preceding treatment options that were based on the patient's age and history of thrombosis. Recent studies using ropeginterferon in low-risk PV patients earlier in the disease course challenge the current treatment paradigm and shift the focus on modifying the co...
Source: Clinical Lymphoma, Myeloma and Leukemia - November 26, 2023 Category: Hematology Authors: Lucia Masarova, Helen T. Chifotides Tags: Review Article Source Type: research
Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell Lymphoma Patients Treated With Epcoritamab
Patient-reported outcomes were evaluated in EPCORE NHL-1 in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) treated with epcoritamab monotherapy (NCT03625037). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 26, 2023 Category: Hematology Authors: Tycel Phillips, Pieternella Lugtenburg, Anupama Kalsekar, Alex Mutebi, Anthony Wang, Julie Blaedel, Katherine Kosa, Susan Martin, Mariana Sacchi, Nurgul Kilavuz, Catherine Thieblemont Tags: Original Study Source Type: research
Multi-parametric flow cytometry in the evaluation of plasma cell proliferative disorders- Current paradigms for clinical practice
Plasma cell proliferative disorders (PCPDs) comprise a spectrum of disorders arising from clonal plasma cells (PCs) with variable disease phenotype ranging from benign premalignant state of Monoclonal Gammopathy of Undetermined Significance (MGUS) to indolent state of Smoldering Multiple Myeloma (SMM) to overt malignant phenotype of Multiple Myeloma (MM), some of which may progress to a clinically aggressive leukemic state of Plasma Cell leukemia (PCL). In MGUS, SMM and MM, the primary disease is intramedullary whereas PCL has a hematogenous spread. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 26, 2023 Category: Hematology Authors: Ritu Gupta, Dragan Jevremovic, Smith J. Mathew, Shaji Kumar Tags: Review Article Source Type: research
SOHO State of the Art Update and Next Questions | Novel Therapies for Polycythemia Vera
In the recent years, landmark advancements in the treatment of polycythemia vera (PV) have been achieved. We witnessed the regulatory approval of ropeginterferon and the advanced clinical development of other novel agents that may affect the underlying pathophysiological mechanisms of the disease. Agents with the potential of disease modification may soon overtake preceding treatment options that were based on the patient's age and history of thrombosis. Recent studies using ropeginterferon in low-risk PV patients earlier in the disease course challenge the current treatment paradigm and shift the focus on modifying the co...
Source: Clinical Lymphoma, Myeloma and Leukemia - November 26, 2023 Category: Hematology Authors: Lucia Masarova, Helen T. Chifotides Tags: Review Article Source Type: research
Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 23, 2023 Category: Hematology Source Type: research
Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 23, 2023 Category: Hematology Source Type: research
